281 related articles for article (PubMed ID: 38600608)
21. Phosphorylation of EZH2 by AMPK Suppresses PRC2 Methyltransferase Activity and Oncogenic Function.
Wan L; Xu K; Wei Y; Zhang J; Han T; Fry C; Zhang Z; Wang YV; Huang L; Yuan M; Xia W; Chang WC; Huang WC; Liu CL; Chang YC; Liu J; Wu Y; Jin VX; Dai X; Guo J; Liu J; Jiang S; Li J; Asara JM; Brown M; Hung MC; Wei W
Mol Cell; 2018 Jan; 69(2):279-291.e5. PubMed ID: 29351847
[TBL] [Abstract][Full Text] [Related]
22. Aberrant expression of EZH2 is associated with pathological findings and P53 alteration.
Shiogama S; Yoshiba S; Soga D; Motohashi H; Shintani S
Anticancer Res; 2013 Oct; 33(10):4309-17. PubMed ID: 24122997
[TBL] [Abstract][Full Text] [Related]
23. Polycomb repressive complex's evolutionary conserved function: the role of EZH2 status and cellular background.
Gall TroĊĦelj K; Novak Kujundzic R; Ugarkovic D
Clin Epigenetics; 2016; 8():55. PubMed ID: 27239242
[TBL] [Abstract][Full Text] [Related]
24. EZH2 promotes invasion and tumour glycolysis by regulating STAT3 and FoxO1 signalling in human OSCC cells.
Zheng M; Cao MX; Luo XJ; Li L; Wang K; Wang SS; Wang HF; Tang YJ; Tang YL; Liang XH
J Cell Mol Med; 2019 Oct; 23(10):6942-6954. PubMed ID: 31368152
[TBL] [Abstract][Full Text] [Related]
25. EZH2 in normal hematopoiesis and hematological malignancies.
Herviou L; Cavalli G; Cartron G; Klein B; Moreaux J
Oncotarget; 2016 Jan; 7(3):2284-96. PubMed ID: 26497210
[TBL] [Abstract][Full Text] [Related]
26. Roles of enhancer of zeste homolog 2: from skeletal muscle differentiation to rhabdomyosarcoma carcinogenesis.
Marchesi I; Giordano A; Bagella L
Cell Cycle; 2014; 13(4):516-27. PubMed ID: 24496329
[TBL] [Abstract][Full Text] [Related]
27. Polycomb Repressive Complex 2 in Oncology.
Guo Y; Yu Y; Wang GG
Cancer Treat Res; 2023; 190():273-320. PubMed ID: 38113005
[TBL] [Abstract][Full Text] [Related]
28. Long non-coding RNA HOTAIR promotes tumor cell invasion and metastasis by recruiting EZH2 and repressing E-cadherin in oral squamous cell carcinoma.
Wu Y; Zhang L; Zhang L; Wang Y; Li H; Ren X; Wei F; Yu W; Liu T; Wang X; Zhou X; Yu J; Hao X
Int J Oncol; 2015; 46(6):2586-94. PubMed ID: 25901533
[TBL] [Abstract][Full Text] [Related]
29. The roles of EZH2 in cancer and its inhibitors.
Liu Y; Yang Q
Med Oncol; 2023 May; 40(6):167. PubMed ID: 37148376
[TBL] [Abstract][Full Text] [Related]
30. Going beyond Polycomb: EZH2 functions in prostate cancer.
Park SH; Fong KW; Mong E; Martin MC; Schiltz GE; Yu J
Oncogene; 2021 Sep; 40(39):5788-5798. PubMed ID: 34349243
[TBL] [Abstract][Full Text] [Related]
31. ZMYND8 preferentially binds phosphorylated EZH2 to promote a PRC2-dependent to -independent function switch in hypoxia-inducible factor-activated cancer.
Tang B; Sun R; Wang D; Sheng H; Wei T; Wang L; Zhang J; Ho TH; Yang L; Wei Q; Huang H
Proc Natl Acad Sci U S A; 2021 Feb; 118(8):. PubMed ID: 33593912
[TBL] [Abstract][Full Text] [Related]
32. Rap1 and its regulatory proteins: the tumor suppressor, oncogene, tumor suppressor gene axis in head and neck cancer.
Banerjee R; Russo N; Liu M; Van Tubergen E; D'Silva NJ
Small GTPases; 2012; 3(3):192-7. PubMed ID: 22684501
[TBL] [Abstract][Full Text] [Related]
33. Polycomb repressive complex 2 regulates normal development of the mouse heart.
He A; Ma Q; Cao J; von Gise A; Zhou P; Xie H; Zhang B; Hsing M; Christodoulou DC; Cahan P; Daley GQ; Kong SW; Orkin SH; Seidman CE; Seidman JG; Pu WT
Circ Res; 2012 Feb; 110(3):406-15. PubMed ID: 22158708
[TBL] [Abstract][Full Text] [Related]
34. Combined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for non-small-cell lung cancer cells.
Takashina T; Kinoshita I; Kikuchi J; Shimizu Y; Sakakibara-Konishi J; Oizumi S; Nishimura M; Dosaka-Akita H
Cancer Sci; 2016 Jul; 107(7):955-62. PubMed ID: 27116120
[TBL] [Abstract][Full Text] [Related]
35. Mutations and deletions of PRC2 in prostate cancer.
Jain P; Di Croce L
Bioessays; 2016 May; 38(5):446-54. PubMed ID: 27000413
[TBL] [Abstract][Full Text] [Related]
36. Small Molecule Approaches for Targeting the Polycomb Repressive Complex 2 (PRC2) in Cancer.
Martin MC; Zeng G; Yu J; Schiltz GE
J Med Chem; 2020 Dec; 63(24):15344-15370. PubMed ID: 33283516
[TBL] [Abstract][Full Text] [Related]
37. Ubiquitous expressed transcript promotes tumorigenesis by acting as a positive modulator of the polycomb repressive complex 2 in clear cell renal cell carcinoma.
Zeng J; Xiang W; Zhang Y; Huang C; Chen K; Chen Z
BMC Cancer; 2019 Sep; 19(1):874. PubMed ID: 31481081
[TBL] [Abstract][Full Text] [Related]
38. JARID2 and EZH2, the eminent epigenetic drivers in human cancer.
Sreeshma B; Devi A
Gene; 2023 Aug; 879():147584. PubMed ID: 37353042
[TBL] [Abstract][Full Text] [Related]
39. STAT3/HOTAIR Signaling Axis Regulates HNSCC Growth in an EZH2-dependent Manner.
Sun S; Wu Y; Guo W; Yu F; Kong L; Ren Y; Wang Y; Yao X; Jing C; Zhang C; Liu M; Zhang Y; Zhao M; Li Z; Wu C; Qiao Y; Yang J; Wang X; Zhang L; Li M; Zhou X
Clin Cancer Res; 2018 Jun; 24(11):2665-2677. PubMed ID: 29540490
[No Abstract] [Full Text] [Related]
40. Inactivation of Ezh2 Upregulates Gfi1 and Drives Aggressive Myc-Driven Group 3 Medulloblastoma.
Vo BT; Li C; Morgan MA; Theurillat I; Finkelstein D; Wright S; Hyle J; Smith SMC; Fan Y; Wang YD; Wu G; Orr BA; Northcott PA; Shilatifard A; Sherr CJ; Roussel MF
Cell Rep; 2017 Mar; 18(12):2907-2917. PubMed ID: 28329683
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
